{"id":72142,"date":"2026-08-10T12:33:30","date_gmt":"2026-08-10T04:33:30","guid":{"rendered":"https:\/\/flcube.com\/?p=72142"},"modified":"2026-08-10T12:33:31","modified_gmt":"2026-08-10T04:33:31","slug":"sino-biopharmas-benmelstobart-anlotinib-combo-wins-nmpa-nod-for-first-line-sq-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72142","title":{"rendered":"Sino Biopharma&#8217;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1177:HKG\">HKG:\u202f1177<\/a>) announced that <strong>benmelstobart<\/strong> in combination with chemotherapy, sequentially followed by <strong>anlotinib<\/strong>, has been granted <strong>marketing approval<\/strong> by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for the <strong>first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC)<\/strong>. Both drugs are <strong>Category\u202f1 innovative medicines<\/strong> developed by Sino Biopharma\u2019s subsidiary <strong>Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ)<\/strong>. This marks the <strong>12th approved indication<\/strong> for anlotinib and the <strong>6th approved indication<\/strong> for benmelstobart.<\/p>\n\n\n\n<h2 id=\"h-approval-snapshot\" class=\"wp-block-heading\">Approval Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sino Biopharmaceutical Limited (HKG:\u202f1177)<\/td><\/tr><tr><td><strong>Subsidiary<\/strong><\/td><td>Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing approval (Category\u202f1 innovative drug)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>Benmelstobart + chemotherapy \u2192 anlotinib + benmelstobart (sequential)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line locally advanced or metastatic sq\u2011NSCLC<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>07\u202fAug\u202f2026<\/td><\/tr><tr><td><strong>Indication Tally<\/strong><\/td><td>Anlotinib: 12th; Benmelstobart: 6th<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Benmelstobart:<\/strong> Anti\u2011<strong>PD\u2011L1<\/strong> monoclonal antibody (mAb); blocks the programmed death\u2011ligand\u202f1 pathway to restore T\u2011cell\u2011mediated anti\u2011tumor immunity.<\/li>\n\n\n\n<li><strong>Anlotinib:<\/strong> Oral <strong>multi\u2011target tyrosine kinase inhibitor<\/strong>; suppresses tumor angiogenesis and proliferation by inhibiting VEGFR, PDGFR, FGFR, and c\u2011Kit, among other targets.<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Sequential immunotherapy plus targeted anti\u2011angiogenesis aims to overcome primary resistance and extend durable disease control beyond what either monotherapy or chemo\u2011immunotherapy alone typically achieves.<\/li>\n\n\n\n<li><strong>Prior Indications in China:<\/strong> Endometrial cancer, extensive\u2011stage small cell lung cancer (ES\u2011SCLC), and first\u2011line renal cell carcinoma, among others.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-eter700-phase-3-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 ETER700 Phase\u202f3 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Benmelstobart + Chemo \u2192 Anlotinib + Benmelstobart<\/th><th>Tislelizumab + Chemo (Control)<\/th><th>Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>mPFS<\/strong><\/td><td><strong>11.20\u202fmonths<\/strong><\/td><td>8.28\u202fmonths<\/td><td><strong>+2.92\u202fmonths<\/strong><\/td><\/tr><tr><td><strong>mOS<\/strong><\/td><td><strong>Not reached<\/strong><\/td><td>26.45\u202fmonths<\/td><td>Statistically significant<\/td><\/tr><tr><td><strong>ORR<\/strong><\/td><td><strong>76.33\u202f%<\/strong><\/td><td>71.78\u202f%<\/td><td><strong>+4.55\u202fppt<\/strong><\/td><\/tr><tr><td><strong>mDoR<\/strong><\/td><td><strong>13.14\u202fmonths<\/strong><\/td><td>11.07\u202fmonths<\/td><td><strong>+2.07\u202fmonths<\/strong><\/td><\/tr><tr><td><strong>Discontinuation Due to AEs<\/strong><\/td><td><strong>8.8\u202f%<\/strong><\/td><td>9.8\u202f%<\/td><td><strong>\u20131.0\u202fppt<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The head\u2011to\u2011head study demonstrated <strong>consistent benefits across subgroups<\/strong>, including patients with varying <strong>PD\u2011L1 expression levels<\/strong>. The safety profile was manageable, with a slightly lower rate of treatment discontinuation due to adverse events in the study arm versus the control arm.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China sq\u2011NSCLC Landscape:<\/strong> Squamous NSCLC accounts for roughly <strong>25\u201330\u202f%<\/strong> of all lung cancer cases in China and has historically been challenging to treat due to limited targeted therapy options outside of immunotherapy combinations. A domestically developed, sequential chemo\u2011immuno\u2011TKI regimen offers a new standard\u2011of\u2011care contender.<\/li>\n\n\n\n<li><strong>Head\u2011to\u2011Head Differentiation:<\/strong> By beating <strong>tislelizumab<\/strong> (BeiGene\u2019s blockbuster PD\u20111 inhibitor) on both PFS and OS in a direct comparison, the benmelstobart\u2011anlotinib regimen gains a compelling commercial narrative for hospital formulary inclusion and physician adoption.<\/li>\n\n\n\n<li><strong>Portfolio Synergy:<\/strong> With <strong>12 indications<\/strong> for anlotinib and <strong>6 for benmelstobart<\/strong>, CTTQ is building a broad\u2011based oncology franchise that leverages cross\u2011selling and combination\u2011therapy bundling across multiple tumor types.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts estimate the China first\u2011line sq\u2011NSCLC market could exceed <strong>\u00a58\u202fbillion<\/strong> (\u2248\u202fUS$1.1\u202fbillion) annually by 2028. Sino Biopharma\u2019s sequential regimen, if priced competitively against imported PD\u20111\/PD\u2011L1 combinations, could capture a meaningful share of this volume.<\/li>\n\n\n\n<li><strong>Pipeline Momentum:<\/strong> Additional combination trials in other solid tumors are expected to read out over the next 12\u201318 months, potentially expanding the label further.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the commercial potential of the benmelstobart\u2011anlotinib combination in China, revenue projections, and future pipeline developments. Actual results may differ materially due to risks including reimbursement negotiations, competitive dynamics, physician adoption rates, and regulatory requirements for new indications. Investors should consult official filings for updated risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700982_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080700982_c.\"><\/object><a id=\"wp-block-file--media-34ef503e-8590-4e7e-ad4a-4b1c2dd66ea0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700982_c.pdf\">2026080700982_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080700982_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-34ef503e-8590-4e7e-ad4a-4b1c2dd66ea0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[661,29,908,18,15,313,33],"class_list":["post-72142","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-chia-tai-tianqing-pharmaceutical","tag-combination-therapy","tag-hkg-1177","tag-pd-1-l1","tag-product-approvals","tag-sino-biopharmaceutical","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharma&#039;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC). Both drugs are Category\u202f1 innovative medicines developed by Sino Biopharma\u2019s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72142\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharma&#039;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC). Both drugs are Category\u202f1 innovative medicines developed by Sino Biopharma\u2019s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72142\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T04:33:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T04:33:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72142#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72142\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharma&#8217;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC\",\"datePublished\":\"2026-08-10T04:33:30+00:00\",\"dateModified\":\"2026-08-10T04:33:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72142\"},\"wordCount\":566,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"Combination therapy\",\"HKG: 1177\",\"PD-1\\\/L1\",\"Product approvals\",\"Sino Biopharmaceutical\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72142#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72142\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72142\",\"name\":\"Sino Biopharma's benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-10T04:33:30+00:00\",\"dateModified\":\"2026-08-10T04:33:31+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC). Both drugs are Category\u202f1 innovative medicines developed by Sino Biopharma\u2019s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72142#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72142\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72142#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharma&#8217;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharma's benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC). Both drugs are Category\u202f1 innovative medicines developed by Sino Biopharma\u2019s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72142","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharma's benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC","og_description":"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC). Both drugs are Category\u202f1 innovative medicines developed by Sino Biopharma\u2019s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.","og_url":"https:\/\/flcube.com\/?p=72142","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T04:33:30+00:00","article_modified_time":"2026-08-10T04:33:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72142#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72142"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharma&#8217;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC","datePublished":"2026-08-10T04:33:30+00:00","dateModified":"2026-08-10T04:33:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72142"},"wordCount":566,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chia Tai Tianqing Pharmaceutical","Combination therapy","HKG: 1177","PD-1\/L1","Product approvals","Sino Biopharmaceutical","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72142#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72142","url":"https:\/\/flcube.com\/?p=72142","name":"Sino Biopharma's benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-10T04:33:30+00:00","dateModified":"2026-08-10T04:33:31+00:00","description":"Sino Biopharmaceutical Limited (HKG:\u202f1177) announced that benmelstobart in combination with chemotherapy, sequentially followed by anlotinib, has been granted marketing approval by China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of locally advanced or metastatic squamous non\u2011small cell lung cancer (sq\u2011NSCLC). Both drugs are Category\u202f1 innovative medicines developed by Sino Biopharma\u2019s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ). This marks the 12th approved indication for anlotinib and the 6th approved indication for benmelstobart.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72142#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72142"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72142#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharma&#8217;s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72142"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72142\/revisions"}],"predecessor-version":[{"id":72144,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72142\/revisions\/72144"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}